危重症患者消化道出血预防的疗效与安全性:系统综述与网状Meta分析
结果显示高出血风险患者中PPIs和H2RAs可能减少临床重要消化道出血,但可能增加肺炎风险,对死亡率无明确影响。
要点
- 高出血风险(>8%或4-8%)危重症患者,PPIs和H2RAs可能减少临床重要消化道出血。
- PPIs和H2RAs相比无预防可能增加肺炎风险,证据确定性低。
- PPIs和H2RAs对死亡率、艰难梭菌感染、ICU住院时间等无明确影响。
核心结论
- 对于出血风险较高的危重症患者,PPIs和H2RAs相比无预防可能显著减少消化道出血。
- 对于低出血风险患者,出血减少可能不重要。
- PPIs和H2RAs可能显著增加肺炎风险,对死亡率或其他院内结局无重要影响。
研究设计与样本
- 系统综述与网状Meta分析,纳入比较PPIs、H2RAs或硫糖铝与安慰剂或无预防的随机对照试验。
- 检索Medline、PubMed、Embase、Cochrane CENTRAL、试验注册库及灰色文献至2019年3月。
- 采用随机效应模型进行配对和网状Meta分析,使用GRADE评估证据确定性。
主要发现
- 最高风险(>8%)患者中,PPIs减少临床重要消化道出血(OR 0.61,95%CI 0.42-0.89),绝对减少3.3%,中等确定性。
- 高风险(4-8%)患者中,PPIs减少出血绝对减少2.3%,中等确定性。
- 最高风险患者中,H2RAs减少出血(OR 0.46,95%CI 0.27-0.79),绝对减少4.6%,中等确定性。
- 高风险患者中,H2RAs减少出血绝对减少3.1%,中等确定性。
- PPIs可能增加肺炎风险(OR 1.39,95%CI 0.98-2.10),绝对增加5.0%,低确定性;H2RAs可能增加肺炎风险(OR 1.26,95%CI 0.89-1.85),绝对增加3.4%,低确定性。
关键数值与推荐
- 纳入标准:成人危重症患者,比较PPIs、H2RAs或硫糖铝与安慰剂或无预防的随机对照试验。
- 排除标准:未明确报告。
临床怎么用
- 对于出血风险较高的危重症患者,可考虑使用PPIs或H2RAs预防消化道出血。
- 对于低出血风险患者,预防性使用PPIs或H2RAs的获益可能有限。
- 使用PPIs或H2RAs时需权衡肺炎风险增加的可能性。
局限性
- 部分结局证据确定性低,尤其肺炎风险。
- 研究间存在异质性,部分结果受高偏倚风险研究影响。
- 检索截止2019年3月,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine, in critically ill patients, the relative impact of proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), sucralfate, or no gastrointestinal bleeding prophylaxis (or stress ulcer prophylaxis) on outcomes important to patients. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Medline, PubMed, Embase, Cochrane Central Register of Controlled Trials, trial registers, and grey literature up to March 2019. ELIGIBILITY CRITERIA FOR SELECTING STUDIES AND METHODS: We included randomised controlled trials that compared gastrointestinal bleeding prophylaxis with PPIs, H2RAs, or sucralfate versus one another or placebo or no prophylaxis in adult critically ill patients. Two reviewers independently screened studies for eligibility, extracted data, and assessed risk of bias. A parallel guideline committee (BMJ Rapid Recommendation) provided critical oversight of the systematic review, including identifying outcomes important to patients. We performed random-effects pairwise and network meta-analyses and used GRADE to assess certainty of evidence for each outcome. When results differed between low risk and high risk of bias studies, we used the former as best estimates. RESULTS: Seventy two trials including 12 660 patients proved eligible. For patients at highest risk (>8%) or high risk (4-8%) of bleeding, both PPIs and H2RAs probably reduce clinically important gastrointestinal bleeding compared with placebo or no prophylaxis (odds ratio for PPIs 0.61 (95% confidence interval 0.42 to 0.89), 3.3% fewer for highest risk and 2.3% fewer for high risk patients, moderate certainty; odds ratio for H2RAs 0.46 (0.27 to 0.79), 4.6% fewer for highest risk and 3.1% fewer for high risk patients, moderate certainty). Both may increase the risk of pneumonia compared with no prophylaxis (odds ratio for PPIs 1.39 (0.98 to 2.10), 5.0% more, low certainty; odds ratio for H2RAs 1.26 (0.89 to 1.85), 3.4% more, low certainty). It is likely that neither affect mortality (PPIs 1.06 (0.90 to 1.28), 1.3% more, moderate certainty; H2RAs 0.96 (0.79 to 1.19), 0.9% fewer, moderate certainty). Otherwise, results provided no support for any affect on mortality, Clostridium difficile infection, length of intensive care stay, length of hospital stay, or duration of mechanical ventilation (varying certainty of evidence). CONCLUSIONS: For higher risk critically ill patients, PPIs and H2RAs likely result in important reductions in gastrointestinal bleeding compared with no prophylaxis; for patients at low risk, the reduction in bleeding may be unimportant. Both PPIs and H2RAs may result in important increases in pneumonia. Variable quality evidence suggested no important effects of interventions on mortality or other in-hospital morbidity outcomes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019126656.
引用
- Wang Y, Ye Z, Ge L, et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ. 2020. PMID: 31907166. doi:10.1136/bmj.l6744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。